Tag: equity
-
Johnson & Johnson Acquires Biotech Developing Anti-Virals
30 September 2014. The biotechnology company Alios BioPharma Inc., a developer of anti-viral medications, is being acquired by health care products enterprise Johnson & Johnson for $1.75 billion. The all-cash deal will add Alios BioPharma’s pipeline to the portfolio of Janssen Pharmaceuticals, a division of Johnson & Johnson. Alios BioPharma, in South San Francisco, California,…
-
Investment Fund Launches to Support Stem Cell Ventures
29 September 2014. ReproCell Inc., a developer of stem cell lines for research and therapies in Yokohama, Japan, is starting an investment fund that aims to back new biotechnology companies bringing stem cell research to market. The fund, called Cell Innovation Partners, begins with ¥800 million ($US 7.3 million) in capital, provided by Shinsei Corporate…
-
Sanofi, MyoKardia Partner on Genetic Heart Disorders
17 September 2014. The pharmaceutical company Sanofi and biopharmaceutical developer MyoKardia are collaborating on development and commercialization of three MyoKardia therapies for inherited heart diseases. The deal could earn MyoKardia as much as $200 million in milestone payments and equity investments from Sanofi. MyoKardia, in South San Francisco, California, designs small-molecule therapies for two types…
-
Asthma/COPD Device Maker Lands $14.5M in Venture Funds
5 September 2014. Propeller Health in Madison, Wisconsin, developer of a system to track respiratory disorder medications in real time, secured $14.5 million in its second round of venture financing. The funding round was led by venture investment company Safeguard Scientifics, with participation by the Social+Capital Partnership, Propeller Health’s previous funding source. The Propeller Health…
-
Calico, AbbVie Partner on Aging Disorder Therapies
3 September 2014. California Life Sciences LLC, better known as Calico, and the pharmaceutical company AbbVie Inc. are collaborating on discovery and commercialization of drugs for age-related diseases such as cancer and neurodegenerative disorders. The partnership, which includes building a new research center, could result in a joint investment as high as $1.5 billion. Calico,…
-
New Medical Technologies Investment Fund Raises $110M
19 August 2014. HealthQuest Capital, a spin-off investment firm, says it raised $110 million for funding in technology-based start-ups serving the health care industry. The company was spun off from Sofinnova Ventures in Menlo Park, California and founded by Garheng Kong, a Sofinnova general partner. HealthQuest plans to invest in companies developing medical devices, diagnostics, patient-care…
-
Novartis Acquires Stake in Stem Cell Therapy Company
19 August 2014. Gamida Cell, a developer of therapies from umbilical cord stem cells, says the global pharmaceutical company Novartis is buying a 15 percent interest in the company, with an option to acquire the entire company later. The deal brings Gamida Cell, located in Jerusalem, Israel, $35 million immediately, with a total potential return…
-
Middle, Inner Ear Drug Developer Raises $100M in IPO
13 August 2014. Otonomy Inc., a biopharmaceutical company in San Diego developing treatments for disorders of the middle and inner ear, raised $100 million in its initial public offering of stock. The company, trading on the NASDAQ under the symbol OTIC, priced its 6.25 million shares at $16.00. Otonomy was founded in 2008 by physicians…
-
Licensing Deal Combines Genomics, Placenta Stem Cells
11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected to make an equity investment…
-
Immunotherapy Start-Up Adds $134M in Venture Funding
5 August 2014. Juno Therapeutics, a biotechnology company in Seattle developing cancer treatments that harness the human immune system, secured $134 million in its second round of venture financing. The company, a spin-off enterprise from research labs in Seattle and New York, says the new round was provided by 10 public mutual funds and health…